University of Massachusetts Amherst researchers reported a nanoparticle vaccine platform that, when paired with cancer‑specific antigens, prevented tumor formation and metastasis in multiple mouse models including melanoma, pancreatic cancer and triple‑negative breast cancer. Published in Cell Reports Medicine and led by Prabhani Atukorale, the study shows multi‑pathway innate immune activation via engineered nanoparticles produced high rates of tumor‑free survival (up to 88% in some models). The group framed the particles as a solution to incompatible adjuvant chemistries — the nanoparticles co‑deliver multiple danger signals to prime stronger adaptive responses. Investigators said the platform is modular and could serve as a base for therapeutic or preventive cancer vaccines pending translational work.